FDA maintains US hold on Hemopure, but non-US trials move ahead
This article was originally published in Clinica
The US FDA has dealt a further blow to US blood substitute developer Biopure by maintaining the clinical hold on the IND application for its proposed RESUS phase II/III clinical trial of (Hemopure haemoglobin glutamer-250 (bovine)) for out-of-hospital treatment of trauma patients.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.